Sorafenib in NF2

• Research type

  Research Study

• Full title

  Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas

• IRAS ID

  79694

• Sponsor organisation

  PHNT

• Eudract number

  2011-001789-16

• ISRCTN Number

  not sent

• Research summary

  This is a small study of 14 patients with a hereditary tumour syndrome called Neurofibromatosis 2 (NF2) in Plymouth and Manchester. Patients will have a biopsy of a cutaneous tumour prior to treatment with Sorafenib for 11 days. On Day 11 of treatment, a second (post-dose) biopsy will be taken. The aim of the study is to investigate the uptake and activity of the drug sorafenib in the cutaneous tumours, specifically whether it inhibits the molecular pathways it should. Patients have safety assessments at Day 7 and Day 11 of dosing and are followed up at 28 days (2 days) after the first dose of sorafenib.

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  11/LO/0771

• Date of REC Opinion

  26 Aug 2011

• REC opinion

  Further Information Favourable Opinion